Supriya Lifescience Delivers Strong Q3 FY26 Results with 11% YoY Revenue Growth

The unaudited financial statements for Q3FY26 have been released by Supriya Lifescience Ltd., a cGMP-compliant business with a strong track record in API manufacturing and a focus on products from a variety of therapeutic segments, including anti-histamine, anti-allergic, vitamin, anaesthetic, and anti-asthmatic. The company has spread its business in more than 120 countries across the globe.

Key Highlights for Q3 FY26:

In Q3 FY26, Supriya Lifescience Ltd. witnessed a 11.2 % year-over-year growth in Revenue to Rs 206.44 crore compared to Rs 185.65 crore in Q3 FY25.

EBITDA for Q3 FY26 stood at Rs 72.08 crore, with an EBITDA margin of 34.9%, as against Rs 65.96 crore in Q3 FY25 with a margin of 35.5%.

The Profit After Tax (PAT) for Q3 FY26 was Rs 49.68 crore, compared to Rs 46.78 crore in Q3 FY25.

The PAT Margin stood at 24.1% in Q3 FY26 versus 25.2% in Q3 FY25.

The anesthetic segment emerged as the primary growth driver in 9M FY26, contributing 54% of total revenues, compared to 48% in 9M FY25. The vitamins segment also witnessed improved traction, with its contribution increasing from 11% to 12% during the same period.

Growth was driven by Latin American market. Contribution of LatAm markets grew to 24% from 21% while the share of North America in the business mix went up to 6% in Q3FY26 from 3% over the last two quarters. However, Europe continues to be the Company's largest market, accounting for 36% of business revenues in Q3 FY26 followed by Asia at 32%.

Capacity utilisation improved significantly, recovering from 70% in FY25 to 76% in 9MFY26. To support future growth across business segments, the Company has acquired three land parcels located near its existing manufacturing facilities, strengthening its long-term expansion plans.

Mr. Satish Wagh, Executive Chairman and Whole Time Director, Supriya Lifescience Ltd, commenting on the results, said, "Our performance this quarter reflects consistent execution and sustained profitability, supported by steady demand across key global markets. Exports continued to remain a strong contributor, accounting for approximately 82% of revenues in Q3, with Europe forming a significant share of the business mix. Capacity utilisation improved to around 76% during 9MFY26, aided by the ramp-up of Module E at our Lote Parshuram facility, enhancing operational efficiency and supply reliability. As we prepare for the commercial launch of our Ambernath formulation facility in Q4 FY26 and continue to deepen our presence in regulated markets through backward integration and new product introductions, we remain confident of driving stronger growth in the coming quarters."

Shares of Supriya Lifescience Limited was last trading in BSE at Rs. 687.70 as compared to the previous close of Rs. 668.95. The total number of shares traded during the day was 8075 in over 495 trades.

The stock hit an intraday high of Rs. 690.80 and intraday low of 655.75. The net turnover during the day was Rs. 5468270.00.

Source : Equity Bulls

Keywords

SupriyaLifescience INE07RO01027 Pharmaceuticals Q3FY26 Q3FY2026 9MFY26 9MFY2026 ResultUpdate